Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1701

Contact Lens Drug Delivery Device

Inventors: Daniel Kohane, Joseph Ciolino

Invention Types: Therapeutics, Medical Device

Research Areas: Ophthalmology, Anesthesia

Keywords: Instrumentation, Method of Use

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Dr. Daniel Kohane and Joseph Ciolino have developed a method of delivering one or more drugs to the eye through the use of contact lens as a drug delivery device (CLDDD). The CLDDD delivers a medication to the eye at a constant rate and in a unidirectional manner over a period of weeks to months.


Many eye conditions and ocular diseases such as glaucoma receive first line treatment with medications applied topically directly to the eye surface. It is estimated that of the medications delivered to the eye in the form of an eye drop, only 1-7% is absorbed by the cornea. Furthermore, 80% of an eye drop is lost after one blink. Most of the remaining eye drop is drained through the tear duct and nasal-lacrimal system, which is then absorbed systemically-- the result of which can be low blood pressure, heart failure and shortness of breath. The difficulty for some patients in self-administering eye drops in the home, and issues related to adherence, also leads to serious side effects.


Drs. Kohane and Ciolino designed the lens in a way such that the drugs are entrapped in a solid degradable scaffold. The CLDDD consists of a drug-polymer film encapsulated within a contact lens. Both the film construction and the encapsulation method developed with this technology are integral for facilitating the uniform drug release observed. The design also allows for different quantities of drug loadings and drug delivery lifetimes (from one day to as long as a month), pursuant to various existing treatment plans. The CLDDD is therefore designed to deliver medication to a patient in a manner that is both more effective and less cumbersome than existing treatments. Currently, the lens is being developed to deliver latanoprost to treat glaucoma, a leading cause of preventable blindness.

Applications:

Contact Lens Drug Delivery Device provides a minimally-invasive technique for controlled, effective, short or long-term release of a drug directly onto the surface of the eye for a variety of eye conditions and ocular diseases.

Competitive Advantages:

• Several researchers have investigated the use of contact lenses for drug delivery. However, all of the studies demonstrated an early burst and then failed to release a drug in a controlled fashion for longer than four days. The previous research used either drug encapsulated liposomes which were then mixed into the contact lens material or a biomimetic contact lens drug delivery system.

• CLDDD encourages increased absorption of medication.

• Releases medication in a controlled manner.

• Requires no substantive patient compliance.

• Can be administered for up to a month.

Business Opportunity:

Exclusive or non-exclusive license

Key Publications: Joseph B. Ciolino, Cristina F. Stefanescu, Amy E. Ross, Borja Salvador-Culla, Priscila Cortez, Eden M. Ford, Kate A. Wymbs, Sarah L. Sprague, Daniel R. Mascoop, Shireen S. Rudina, Sunia A. Trauger, Fabiano Cade, Daniel S. Kohane. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials, 2014; 35 (1): 432 DOI: 10.1016/j.biomaterials.2013.09.032

IPStatus: Patented